| CAS NO: | 1029877-94-8 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 475.47 |
|---|---|
| Formula | C22H26FN5O6 |
| CAS No. | 1029877-94-8 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 10 mM |
| Water: N/A | |
| Ethanol: N/A | |
| Solubility (In vivo) | Chemical Name:
(R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile
succinate InChi Key: OGCNTTUPLQTBJI-XFULWGLBSA-N InChi Code: InChI=1S/C18H20FN5O2.C4H6O4/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20;5-3(6)1-2-4(7)8/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3;1-2H2,(H,5,6)(H,7,8)/t15-;/m1./s1 SMILES Code: O=C(O)CCC(O)=O.N#CC1=CC=C(F)C=C1CN(C(N2C)=O)C(N3C[C@H](N)CCC3)=CC2=O |
| Synonyms | SYR-472; SYR472; SYR 472; SYR 472; Trelagliptin, Trelagliptin succinate; brand name: Zafatek. |
| In Vitro | In vitro activity: Trelagliptin (also known as SYR-472) is a potent, highly selective, long-acting DPP-4 (dipeptidyl peptidase-4) inhibitor under development by Takeda for the treatment of type 2 diabetes (T2D).. Once-weekly Trelagliptin treatment produced clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. It was well tolerated and might be a new treatment option for patients with this disease. Trelagliptin was approved in Japan for the treatment of type 2 diabetes mellitus (T2DM). |
|---|---|
| In Vivo | Trelagliptin improves glycaemic control by inhibition of DPP-4 activity. |
| Animal model | |
| Formulation & Dosage | |
| References | Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32. |
m.cnreagent.com